Compare research programmes
Compare factual records. Programmes can target different organs and diseases, so the table does not rank their clinical value.
| Record | ER-100 | Rentosertib |
|---|---|---|
| Organisation | Life Biosciences | Insilico Medicine |
| Field | Cellular reprogramming | AI and biological discovery |
| Development record | Human study | Published human results |
| Evidence includes | Cells, Animals, Humans | Cells, Animals, Humans |
| AI’s recorded role | No programme-specific AI contribution verified | PandaOmics helped prioritise TNIK as a fibrosis target; Chemistry42 generated candidate inhibitors that researchers synthesised and tested. |
| Research question | ER-100 brings controlled cellular reprogramming into a Phase 1 study of optic nerve disease. Life Biosciences has announced an interim presentation for 8 October 2026. As of 4 October, those findings have not been presented in the verified sources. | Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental. |
| Next assessment | Life Biosciences has scheduled its interim presentation for 8 October 2026. Participant numbers, follow-up, adverse events and visual outcomes will determine what those findings establish. The registry's estimated completion dates remain planning information. | GENESIS-IPF-3 is the next major clinical test. Its registered endpoints and subsequent results will address lung disease. A broader ageing hypothesis needs experiments that can distinguish disease improvement from effects on ageing in other tissues. |
| Sources | 6 identified sources | 4 identified sources |
Different populations, endpoints and delivery methods can make direct comparisons inappropriate. Read each programme’s study record before interpreting a difference.